Floatz logo

Aclarubicin

Cutaneous T-Cell Lymphoma Refractory

Shanghai Jiao Tong University School of MedicineSmall moleculePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

61 Active assets in the Cutaneous T-Cell Lymphoma Refractory cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Cyclophosphamide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Bexarotene
Case Comprehensive Cancer Center
Phase 4BBB
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 2BBB
FILGRASTIM
City of Hope Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

Aclarubicin is also rated in:

acute myeloid leukemiaDormant
B
Indicative ·
63 / 100
View asset →
Induction ChemotherapyDormant
B
Indicative ·
60 / 100
View asset →
LisaftoclaxDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →